Cancer prevention research (Philadelphia, Pa.)最新文献

{"title":"Proteomic Analysis of Sphingolipid Metabolic Enzymes with Risk of Bladder Cancer Incidence and Mortality in the Atherosclerosis Risk in Communities Study.","authors":"Michael T Marrone, Evan Bagley, Kenneth R Butler, David J Couper, Corinne E Joshu, Elizabeth A Platz, Besim Ogretmen","doi":"10.1158/1940-6207.CAPR-25-0499","DOIUrl":"10.1158/1940-6207.CAPR-25-0499","url":null,"abstract":"<p><p>Lipid metabolism is regarded as a hallmark of cancer. Sphingolipids, a family of structural and signaling lipids, have antiproliferative (ceramides) or prosurvival [sphingosine 1-phosphate (S1P)] functions. The positive association between statin use and bladder cancer, unlike other cancers, suggests that lipid metabolism not affected by HMG-CoA reductase inhibition may contribute uniquely to this cancer. We conducted a hypothesis-generating study investigating associations between plasma sphingolipid metabolic enzymes and bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities study. Among 10,129 men and women with proteomic profiling of plasma collected in 1993 to 1995, 158 incident bladder cancer cases and 47 bladder cancer deaths were ascertained over a median of 20 years of follow-up (164,013 person-years). Cox regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for protein tertiles adjusted for age, race, sex, and known cancer risk factors, including smoking status, pack-years smoked, and cholesterol-lowering medication use. Of the six sphingolipid enzymes, sphingosine kinase 1 (SPHK1), involved in S1P synthesis, was associated with an increased risk of bladder cancer incidence [tertile 3 (T3) vs. T1: HR, 1.74; 95% CI, 1.15-2.63; P trend = 0.008] and bladder cancer mortality (T3 vs. T1: HR, 2.39; 95% CI, 1.02-5.61; P trend = 0.06). Associations for incidence were attenuated in lagged analyses, suggesting potential reverse causation, whereas associations for mortality were unchanged. Our findings suggest that sphingolipid metabolism, specifically enzymes involved in S1P synthesis, may contribute to bladder cancer etiology, with stronger associations in subgroups with lower cholesterol. These findings motivate confirmatory investigation of plasma S1P in relation to bladder cancer outcomes.</p><p><strong>Prevention relevance: </strong>We report a consistent positive association for SPHK1, involved in S1P metabolism, and bladder cancer risk and mortality in our prospective study. Stronger positive associations for SPHK1 were noted in subgroups with lower cholesterol, reflecting a shift in structural and/or signaling lipids to influence bladder cancer initiation.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"565-576"},"PeriodicalIF":2.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13502930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Endoscopic Surveillance in Hereditary Diffuse Gastric Cancer Syndrome.","authors":"Muhan Li, Danielle Lynch, Tanushka Dewan, Kajal Patel, Devanshi Patel, Daniel C Chung","doi":"10.1158/1940-6207.CAPR-26-0102","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-26-0102","url":null,"abstract":"<p><p>Hereditary Diffuse Gastric Cancer (HDGC) syndrome arises from a germline variant in CDH1 and is characterized by a high risk of gastric signet-ring cell carcinoma. Total gastrectomy is the most definitive strategy for cancer risk reduction but carries high morbidity. Endoscopic surveillance is an alternative, but there are limited data on long-term outcomes with this approach. We sought to define the outcomes of long-term endoscopic surveillance in a HDGC cohort. We retrospectively analyzed the demographic, clinical, endoscopic, and histopathological records of 102 patients with pathogenic or likely pathogenic (P/LP) CDH1 variants at Massachusetts General Hospital. We defined short-term endoscopic surveillance as less than 3 years and long-term surveillance as 3 years or longer. The HDGC cohort included 68 female and 34 male patients, with a mean age at diagnosis of 42.1 years. Thirty-four patients opted for immediate risk-reducing gastrectomy and 40 pursued endoscopic surveillance. 20 individuals comprised the short-term surveillance group (median follow-up 1.4 years) and there were 20 individuals in the long-term surveillance group (median follow-up 5.1 years). There were two cases of advanced gastric cancer (>T1a) identified, and both occurred in the long-term surveillance group. Both were managed with gastrectomy and remain cancer-free. There were no gastric cancer-related deaths. In this series, long-term endoscopic surveillance identified advanced gastric cancers in HDGC at treatable stages without any gastric cancer-related mortality. These findings suggest endoscopic surveillance may be a reasonable long-term strategy in HDGC for select individuals.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Neural Network-Enabled, Enzymatic cfDNA Methylation Assay for Colorectal Cancer Early Detection.","authors":"Manny D Bacolod, Almudena Aguilera-Diaz, Philip Feinberg, Somayeh Fani, Jianmin Huang, Francis Barany","doi":"10.1158/1940-6207.CAPR-26-0072","DOIUrl":"10.1158/1940-6207.CAPR-26-0072","url":null,"abstract":"<p><p>Early detection of colorectal cancer remains critical for reducing disease-specific mortality, yet current noninvasive screening approaches have limitations in sensitivity (Sens), patient adherence, and scalability. We developed and clinically evaluated a non-next-generation sequencing (non-NGS) liquid biopsy assay for colorectal cancer detection based on methylation profiling of circulating cell-free DNA (cfDNA). The assay focuses on 40 CpG regions selected via bioinformatics analysis of public methylome datasets and uses a ten-eleven translocation methylcytosine dioxygenase 2-apolipoprotein B mRNA editing enzyme, catalytic polypeptide enzymatic conversion method to maintain cfDNA integrity and enhance amplification efficiency, enabling a rapid and cost-effective quantitative PCR (qPCR)-based workflow. Methylation signals were quantified by qPCR and integrated with patient age using neural network-based predictive models. The assay was evaluated in a cohort of 216 plasma samples, including 86 colorectal cancer cases and 130 healthy controls. In the validation subset, 14 high-performing models demonstrated sensitivities ranging from 80.8% to 92.3% and specificities from 84.6% to 97.4%. A representative model achieved a validation Sens of 92.3% [95% confidence interval (CI), 75%-99%], with early-stage (stage I/II) Sens of 100% (95% CI, 72%-100%) at a specificity of 97.4% (95% CI, 87%-100%). These findings support the potential of an enzymatic conversion-based, machine learning-guided cfDNA methylation assay as a practical, scalable, and minimally invasive approach for colorectal cancer detection. However, the relatively limited number of early-stage cases in this study highlights the need for larger, prospectively collected cohorts to refine performance estimates and confirm clinical utility.</p><p><strong>Prevention relevance: </strong>We present a noninvasive cfDNA methylation assay for early colorectal cancer detection using a non-NGS platform. Improved Sens for early-stage disease may enhance screening uptake and enable timely intervention, supporting colorectal cancer prevention.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"501-516"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editors' Selections from Relevant Scientific Publications.","authors":"","doi":"10.1158/1940-6207.CAPR-19-9-HFL","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-19-9-HFL","url":null,"abstract":"","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":"19 9","pages":"493"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.","authors":"Leigha Senter, Shelly Hovick, Rachel Notestine, Lauren Norden, Nadia Benny, Shannon Phillips, Ava Willoughby, Robert Pyatt, Doreen Agnese, Julie S Mak, Allison DePersia, Sarah V Colonna, Whitney F Maxwell, Wendy Kohlmann, Erika L Spaeth, Ora Gordon, Darcy Thull, Guy N Brock, Amy Webb, Rachel M Smith, Amanda Ewart Toland","doi":"10.1158/1940-6207.CAPR-26-0044","DOIUrl":"10.1158/1940-6207.CAPR-26-0044","url":null,"abstract":"<p><p>Individuals with germline BRCA1 or BRCA2 pathogenic variants (PV) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates Study is a two-arm randomized controlled trial in women with a BRCA1/BRCA2 PV. The primary objective was to determine whether genotype-informed personalized cancer risk estimates (GRE) compared with standard lifetime cancer risk estimates (SRE) decreased decisional conflict related to cancer risk management decision-making. Women were recruited following the disclosure of their PV results. Participants completed a baseline survey and were randomized 1:1 to receive a GRE or SRE. After receiving their results, participants completed a follow-up survey. Likert and continuous data measures were analyzed using linear regression. There were no differences in decisional conflict between study arms at follow-up. However, individuals in the SRE arm showed an increased need for personal structure compared with those in the GRE arm (P = 0.02). Compared with baseline, individuals within the SRE arm showed decreased decisional conflict (P = 0.003) and increased perceived stress (P = 0.02) at follow-up. A more personalized cancer risk estimate did not decrease decisional conflict in women with BRCA1/BRCA2 PVs. Future studies will determine whether a GRE affects actual decision-making behaviors.</p><p><strong>Prevention relevance: </strong>Women with a germline PV in BRCA1 or BRCA2 have significantly elevated risks of developing breast and ovarian cancers. This randomized controlled trial evaluates the impact of polygenic risk scores on decisional conflict related to breast and ovarian cancer prevention and risk management in those with BRCA1/BRCA2 PVs.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"517-528"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Cancer Prevention Needs Both Implementation Science and Ethics.","authors":"Alexandra Wicker, Amanda Courtright-Lim, Lila J Finney Rutten, Steven W Ressler, Jon C Tilburt, Jessica D Austin","doi":"10.1158/1940-6207.CAPR-26-0081","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-26-0081","url":null,"abstract":"<p><p>As technological and genomic innovations continue to advance precision cancer prevention, psychosocial, ethical, and operational complexities increasingly accompany their development. Addressing these challenges will require intentional cross-disciplinary collaboration. We argue that the distinct yet complementary lenses of bioethics and implementation science will be crucial as precision cancer prevention technologies move toward clinical integration. We provide a framework for how this joint effort can be accomplished and sustained across the translational pipeline.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":"19 9","pages":"495-500"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Breast and Cervical Screening Adaptability at a Federally Qualified Health Center.","authors":"Rebecca M Crocker, Jennifer L Schneider, Jennifer S Rivelli, Priyanka Gautom, Anne L Escaron, Gloria D Coronado","doi":"10.1158/1940-6207.CAPR-25-0526","DOIUrl":"10.1158/1940-6207.CAPR-25-0526","url":null,"abstract":"<p><p>Structural barriers to cancer screening at federally qualified health centers (FQHC) have contributed to lower screening rates than those among the broader populace, which were exacerbated by the COVID-19 pandemic. We apply the complex adaptive systems (CAS) theory to understand how one FQHC system in California reshaped its breast and cervical cancer screening programs to minimize health disruptions during the pandemic. This qualitative study, conducted between March 2022 and January 2023, consisted of interviews with clinic leadership and first-line staff, asking them to retrospectively reflect on the clinic's experiences with breast and cervical cancer screening delivery both immediately before and during the pandemic. Interviews were recorded and transcribed, and we performed content analysis and then applied the CAS theory. Participants (n = 20) ranged in age from 26 to 56 years, were mostly female (85%), and held leadership positions (65%). Participants indicated that cervical cancer screening rebounded more quickly than breast cancer screening programs. Results suggest that this difference could potentially be associated with new workflows that were in process prepandemic in the cervical cancer program to address existing screening barriers, as well as the FQHC's flexible approach to pandemic barriers, which included bolstering screening registries, hiring additional female providers, and bundling Pap smears into routine visits. In contrast, breast cancer screening relied on external radiology vendors, which may have reduced its flexibility to adjust to care disruptions. We highlight how healthcare delivery is shaped by interactions among diverse agents and nonlinear processes that occur in a dynamic and interconnected healthcare system.</p><p><strong>Prevention relevance: </strong>We apply the CAS theory to better understand the trajectory of FQHC preventive cancer screening programs during the COVID-19 pandemic. By extending beyond the identification of stand-alone barriers and facilitators, we highlight the ways in which healthcare delivery is shaped by interactions among diverse agents and nonlinear processes.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"529-540"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will They Use It? Patient and Provider Acceptance of Chatbot Screening and Counseling for Hereditary Cancer Syndromes in a Geographically Underserved Population.","authors":"Madison R Coleman, Kaylee A Underkofler, Martha H Thomas, Alisha Gupta, Alayna A Panzer, Kara S Fitzgibbon, Kari L Ring","doi":"10.1158/1940-6207.CAPR-26-0114","DOIUrl":"10.1158/1940-6207.CAPR-26-0114","url":null,"abstract":"<p><p>Screening for pathogenic variants (PV) associated with hereditary cancer syndromes has a positive impact on public health by identifying patients at risk of developing the associated cancers. This survey assesses the current practice of screening for hereditary cancer syndromes and the acceptability of chatbot utilization among primary care providers and residents in rural Southwest Virginia. A two-part survey was conducted among primary care providers and residents in rural Southwest Virginia to assess demographics, health practices, genetic screening practices, and interest in chatbot technology in a geographically underserved population. The response rates for the provider and resident surveys were 8.9% and 19.9%, respectively. A total of 66 providers responded to the survey. One third (32.3%) of providers in our study never screen for hereditary cancer syndromes, and almost two thirds (63.1%) screen their patients for cancer syndromes less than half the time. About 77% of providers felt that chatbots would be useful in identifying patients who need testing and directing what testing to order. Surveys of 476 residential responders showed that 81.9% of residents felt that chatbot technology sounds somewhat to very useful for genetic screening and counseling. More than 57% of residents noted that they would feel comfortable with utilizing chatbot technology to discuss results of genetic screening. Residents and their providers in geographically underserved populations are interested in using chatbots to improve access to genetic testing. Implementation of technology, such as chatbots, in these underresourced settings has the potential to amplify access to genetic counseling and testing.</p><p><strong>Prevention relevance: </strong>This article describes survey results for acceptability of using chatbots for assessing risk and early detection of PVs associated with hereditary cancer syndromes in a rural population. The results could guide further implementation of technology in assisting with early detection and prevention of hereditary cancer syndromes.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"541-547"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Diagnostic Colonoscopy After a Positive Stool-Based Screening Test: A Scoping Review.","authors":"Manali Patel, Paul Gerardo Yeh, Thomas F Imperiale, Victoria L Champion, David R Lairson","doi":"10.1158/1940-6207.CAPR-26-0159","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-26-0159","url":null,"abstract":"<p><p>Non-invasive stool-based colorectal cancer (CRC) screening (e.g., fecal immunochemical test [FIT], guaiac fecal occult blood test [gFOBT], multitarget stool DNA [mt-sDNA]) reduces CRC mortality only when a positive result is followed by timely diagnostic colonoscopy. We synthesized barriers and facilitators to completing diagnostic colonoscopy after a positive stool-based screening test. Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR), we searched PubMed and MEDLINE (Ovid) for English-language, peer-reviewed studies (October 2008- June 2025) reporting barriers, facilitators, or determinants of colonoscopy completion after a positive non-invasive stool-based CRC screening test (FIT, gFOBT, or mt-sDNA). Two reviewers independently abstracted study characteristics and coded barriers/facilitators, which were categorized using a socioecological framework (intrapersonal, interpersonal, organizational, community/environmental, policy). 38 studies directly examined colonoscopy follow-up after a positive non-invasive test. Recurrent barriers included fear/anxiety and low perceived risk (intrapersonal), weak provider recommendation and support (interpersonal), referral and tracking failures and scheduling delays (organizational), transportation and distance (community/environmental), and cost-sharing/coverage gaps (policy). Evidence specifically assessing rural-urban differences was limited. Barriers to diagnostic colonoscopy after a positive stool-based CRC screening test are multi-level and potentially modifiable through improved communication, navigation, and closed-loop tracking. Multicomponent approaches that combine clear communication, navigation and reminder systems, transportation supports, and reduced financial barriers may improve diagnostic completion and equity.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer screening uptake in patients with rheumatoid arthritis in community settings.","authors":"Maria A Lopez-Olivo, Zhigang Duan, Huifang Lu, Robert J Volk, Edwin J Ostrin, Ying Xu, Sharon Giordano, Hui Zhao","doi":"10.1158/1940-6207.CAPR-26-0030","DOIUrl":"10.1158/1940-6207.CAPR-26-0030","url":null,"abstract":"<p><p>Individuals with rheumatoid arthritis (RA), particularly those with a history of smoking, are at increased risk for lung cancer. However, real-world data on the use of low dose computed tomography (LDCT) screening for lung cancer in this population are lacking. Therefore, we assessed the rates, trends, and predictors of LDCT screening among patients with a smoking history and RA. A retrospective cohort study using the IQVIA PharMetrics® Plus for Academics Closed Health Plan claims database was conducted. Patients with RA diagnosed in 2014-2023, aged 50-77 years, and with a history of smoking and no prior cancer or advanced respiratory illness were identified. LDCT screening was identified using Healthcare Common Procedure Coding System codes. Among 15,341 eligible patients, 997 (6.5%) received LDCT screening; median time from RA diagnosis to first LDCT claim was 452 days. In a sensitivity analysis of 12,301 patients with continuous insurance coverage during the 12 months after RA diagnosis, only 367 (3%) underwent LDCT within the first year after RA diagnosis. Demographic factors such as male sex (aOR=1.24; p=0.003), age 55-69 (aOR=~1.90; p<0.0001), and residence outside the West region (p<0.0001) increased uptake. Clinical characteristics and healthcare utilization such as COPD (aOR=2.85; p<0.0001), more outpatient visits (aOR=2.15-2.41; p< 0.001) and DMARD use (aOR=1.27-1.52; p≤ 0.001) also increased odds, whereas greater comorbidity burden reduced screening (aOR=0.79-0.39; p≤0.006). In conclusion, LDCT rates in patients with RA remained low overall and varied according to demographic and clinical factors. Targeted efforts may be needed to improve screening uptake in this high-risk population.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}